Cargando…
KSHV activation, human and viral IL-6 production, and other cytokine dysregulation: Association with the symptomatology of KSHV-associated multicentric Castleman’s disease
Autores principales: | Polizzotto, Mark N, Uldrick, Thomas S, Wang, Victoria, Aleman, Karen, Wyvill, Kathleen M, Marshall, Vickie, Pittaluga, Stefania, O’Mahony, Dierdre, Whitby, Denise, Tosato, Giovanna, Steinberg, Seth M, Little, Richard F, Yarchoan, Robert |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2010
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3002707/ http://dx.doi.org/10.1186/1750-9378-5-S1-A47 |
Ejemplares similares
-
Rituximab combined with liposomal doxorubicin (R-Dox) in HIV-infected patients with severe Kaposi sarcoma-associated herpes virus (KSHV) associated multicentric Castleman disease (MCD)
por: Uldrick, Thomas, et al.
Publicado: (2010) -
Interim results of a clinical trial using oncolytic virotherapy in Kaposi's sarcoma-associated herpesvirus (KSHV) associated-Multicentric Castleman's Disease (MCD)
por: Yarchoan, R, et al.
Publicado: (2009) -
Kaposi sarcoma herpesvirus (KSHV)-associated lymphomas are associated with markedly elevated serum IL-10, elevated IL-6, IL-17 and circulating KSHV
por: Uldrick, Thomas S, et al.
Publicado: (2012) -
Genetic variation in KSHV encoded microRNAs affects microRNA expression and is associated with multicentric Castleman’s disease risk
por: Marshall, Vickie, et al.
Publicado: (2012) -
Clinical Manifestations of Kaposi Sarcoma Herpesvirus Lytic Activation: Multicentric Castleman Disease (KSHV–MCD) and the KSHV Inflammatory Cytokine Syndrome
por: Polizzotto, Mark N., et al.
Publicado: (2012)